Mesothelioma is a malignant condition arising from the pleura and peritoneum that is closely related to asbestos exposure. Due to the prolonged time needed for one to fully develop mesothelioma, difficulty in diagnosing this condition early, its quick progression once manifested, and the limited treatment options, the prognosis for this condition … [Read more...]
Depo-Provera Meningioma Increased Risk Warning in Europe
The European Medicines Agency (EMA) recommended a Depo-Provera meningioma increased risk warning in September 2024. One wonders why the FDA has not followed this EMA regulatory action. Therefore, the Depo-Provera drug label in the US still does not include a warning about the meningioma increased risk associated with Depo-Provera. The following … [Read more...]
Treatment of Pleural Mesothelioma: ASCO Guideline Update
Since the initial [American Society of Clinical Oncologists (ASCO)] clinical practice guideline on the treatment of malignant pleural mesothelioma (PM) was published in 2018 considerable progress has been made which has changed not only the management but even the name of this disease. This guideline update focuses on four key areas: the role of … [Read more...]
Why Are There Depo-Provera Brain Tumor Warnings In Europe But Not US?
Depo-Provera brain tumor lawsuits for women who have been diagnosed with intracranial meningioma, a specific type of brain tumor, are being filed against the responsible pharmaceutical companies. A primary focus of these legal cases will be why the Depo-Provera drug label in the US does not include any warnings about the increased risk of this … [Read more...]
The presence of pleural effusion is an independent prognostic factor in patients with malignant pleural mesothelioma
Abstract: Malignant pleural mesothelioma (MPM) is a rare form of thoracic malignancy with a poor prognosis. Pleural effusion (PE) occurs in the majority of patients with MPM; however, its impact on MPM outcomes remains controversial. We searched for eligible patients from the Surveillance, Epidemiology, and End Results (SEER) database, and … [Read more...]
Andexxa Drug Injury Lawsuits for Blood Clots, PE, DVT
Andexxa (andexanet) is a treatment currently used when the reversal of anticoagulation is needed for life-threatening or uncontrolled bleeding in patients who are using Eliquis (apixaban) or Xarelto (rivaroxaban) at the time. Andexxa drug injury lawsuits for patients who developed blood clots involving a pulmonary embolism (PE) or deep vein … [Read more...]
Ozempic Vision Loss Due to Increased Risk of NAION
Here is the most recent development concerning Ozempic vision loss and blindness: The European Union’s drug regulator said it would assess two new Danish studies that link Novo Nordisk’s popular diabetes drug Ozempic to a rare eye disease. The studies published earlier this week had found Ozempic significantly increases the risk of type 2 … [Read more...]
Diffuse Pleural Mesothelioma: A Challenge in Early Diagnosis
Abstract: We present the clinical case of a 58-year-old female patient, a smoker with occupational exposure to respiratory toxins, who was admitted to our clinic following evaluation in an emergency department, where she was diagnosed with a moderate right pleural effusion. Upon admission, the patient exhibited respiratory symptoms, including … [Read more...]
Ocaliva Label Change Possible After December 2024 FDA Alert
The FDA issued an Ocaliva FDA drug safety alert in December 2024 that may result in another Ocaliva label change. This alert was for cases of liver transplants and liver-related deaths among patients without pre-existing cirrhosis who used Ocaliva as a treatment for primary biliary cholangitis (PBC). To provide context for this most recent … [Read more...]
Andexxa Clotting-Related Deaths and Andexxa Blood Clots
The FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee recently discussed the increased risk of Andexxa clotting-related deaths and Andexxa blood clots seen in the ANNEXA-I trial done for Andexxa, compared with a standard of care reversal agent. This Andexxa Advisory Committee considered the current drug safety profile of Andexxa in … [Read more...]
- 1
- 2
- 3
- …
- 21
- Next Page »